Non Alcoholic Steato Hepatitis(NASH)

Non Alcoholic Steato Hepatitis(NASH)

Last Reviewed : 12/24/2020

Non-alcoholic steatohepatitis is fatty liver disease due to causes other than alcohol. No pharmacological treatment has received approval as of 2015 for NASH. Some studies suggest diet, exercise, and antiglycemic drugs may alter the course of the disease. General recommendations include improving metabolic risk factors and reducing alcohol intake. NASH was first described in 1980 in a series of patients of the Mayo Clinic. Its relevance and high prevalence were recognized mainly in the 1990s. Some think NASH is a diagnosis of exclusion, and many cases may in fact be due to other causes. Non-alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD, and is regarded as a major cause of cirrhosis of the liver of unknown cause. Most people have a good outcome if the condition is caught in its early stages.

A study using the National Health and Nutrition Examination Survey (NHANES) found a 30% rate of NAFLD in the United States between 2011 and 2012.

We researched this topic for you and found the following best online resources. They are categorized into basic, advanced, and research level based on the extent of information you need. You will be taken to the respective websites by pressing on the links below.




Basic information: national institute of diabetes and digestive and kidney diseases nonalcoholic steatohepatitis web md nonalcoholic steatohepatitis (nash) - topic overview merck manuals(professional version)nonalcoholic steatohepatitis (nash) emedicine health nonalcoholic steatohepatitis (nash) cigna nonalcoholic steatohepatitis health center university of michigan nonalcoholic steatohepatitis


Advanced information: medscape pathology of nonalcoholic steatohepatitis patient steatohepatitis and steatosis (fatty liver) upto date patient information: nonalcoholic fatty liver disease (nafld), including nonalcoholic steatohepatitis (nash) (beyond the basics) intercept nonalcoholic steatohepatitis (nash) world gastroenterology organisation world gastroenterology organisation global guidelines nonalcoholic fatty liver disease
and nonalcoholic steatohepatitis

european association for the study of the liver. "pooled analysis confirms vitamin e as a treatment for non-alcoholic steatohepatitis." sciencedaily. sciencedaily, 23 april 2015. . nonalcoholic fatty liver disease: diagnosis and management by thad wilkins, md et al., am fam physician. 2013 jul 1;88(1):35-42. nonalcoholic fatty liver disease pathology outlines liver and intrahepatic bile ducts-nontumor
hepatitis – noninfectious nonalcoholic steatohepatitis (nash) medscape update on nonalcoholic steatohepatitis


Research: yang m, xu d, liu y, guo x, li w, guo c,et al. (2015) combined serum biomarkers in noninvasive diagnosis of non-alcoholic steatohepatitis. plos one 10(6): e0131664. doi:10.1371/journal.pone.0131664

alshaalan r, aljiffry m, al-busafi s, metrakos p, hassanain m. nonalcoholic fatty liver disease: noninvasive methods of diagnosing hepatic steatosis. saudi j gastroenterol [serial online] 2015 [cited 2016 jul 2];21:64-70. available from: jayashree bagchi chakraborty, fiona oakley, and meagan j. walsh, “mechanisms and biomarkers of apoptosis in liver disease and fibrosis,” international journal of hepatology, vol. 2012, article id 648915, 10 pages, 2012. doi:10.1155/2012/648915 : musso g, gambino r, tabibian jh, ekstedt m, kechagias s, et al. (2014) association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. plos med 11(7): e1001680. doi:10.1371/journal.pmed.1001680 paola dongiovanni, stefano romeo, and luca valenti, “genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis,” biomed research international, vol. 2015, article id 460190, 10 pages, 2015. doi:10.1155/2015/460190 jinsheng yu, sharon marsh, junbo hu, wenke feng, and chaodong wu, “the pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background,” gastroenterology research and practice, vol. 2016, article id 2862173, 13 pages, 2016. doi:10.1155/2016/2862173 vanessa j. lavallard and philippe gual, “autophagy and non-alcoholic fatty liver disease,” biomed research international, vol. 2014, article id 120179, 13 pages, 2014. doi:10.1155/2014/120179 int. j. mol. sci. 2013, 14(10), 19867-19890; doi:10.3390/ijms141019867 review:immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis by luisa vonghia et al., int. j. mol. sci. 2016, 17(4), 548; doi:10.3390/ijms17040548 review:role of serum uric acid and ferritin in the development and progression of nafld by rosa lombardi, giuseppina pisano and silvia fargion int. j. mol. sci. 2016, 17(3), 281; doi:10.3390/ijms17030281 review:mitochondrial molecular pathophysiology of nonalcoholic fatty liver disease: a proteomics approach by natalia nuño-lámbarri int. j. mol. sci. 2013, 14(11), 21833-21857; doi:10.3390/ijms141121833 review:rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis by kento imajo et al., int. j. mol. sci. 2014, 15(5), 8713-8742; doi:10.3390/ijms15058713 review:role of mitochondria in nonalcoholic fatty liver disease by fatiha nassir and jamal a. ibdah int. j. mol. sci. 2016, 17(3), 355; doi:10.3390/ijms17030355 review:type 2 diabetes in non-alcoholic fatty liver disease and hepatitis c virus infection—liver: the “musketeer” in the spotlight by stefano ballestri et al.,

helmy a. endocannabinoids and non-alcoholic steatohepatitis. saudi j gastroenterol [serial online] 2006 [cited 2016 jul 2];12:36-7. available from:


Related videos: nonalcoholic steatohepatitis (nash) - dr. julie heimbach nash (fatty liver) by dr. robert gish managing non-alcoholic steatohepatitis non-alcoholic steatohepatitis (nash): progress toward regulatory approval pathways treatment of non-alcoholic hepatitis and fatty liver disease fatty liver diet guide | how to cure fatty liver with diet tlr9 activation in nonalcoholic steatohepatitis

Please leave your comments:

Related Articles